Health
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EUNovo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight lossWegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announc
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":440,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity.","length":350,"tagName":"p"},{"type":"text","content":"Wegovy® 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP T2D (type 2 diabetes) trial, in participants...